Skip to main content
    P

    PTC Therapeutics Inc (PTCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $63.49
    +0.13 (+0.21%)

    Market Cap: $5.30B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    PTC Therapeutics Inc (PTCT) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect PTC Therapeutics (PTCT) to earn $0.94 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.32B. Of 15 analysts, 13 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 1.87, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 87% of the ratings.

    RatingAnalystsShare
    Strong Buy426.7%
    Buy960.0%
    Hold213.3%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    15

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 239.4% and revenue estimates rise 8.3%.

    Fiscal year ending Dec 31, 2026
    $0.94
    EPS consensus, revenue $1.32B
    Fiscal year ending Dec 31, 2027
    $3.19
    EPS consensus, revenue $1.43B
    Next report
    Feb 17, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.94$0.73 to $1.142$1.32B$1.29B to $1.34B14
    Dec 31, 2027$3.19$3.04 to $3.342$1.43B$1.18B to $1.67B14

    Quarterly Estimates

    The EPS consensus rises from $0.40 for the quarter ending Dec 31, 2026 to $0.52 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.40$0.09 to $0.9417$336.93M$297.21M to $365.40M15
    Mar 31, 2027$0.52-$0.01 to $1.387$313.41M$291.64M to $341.40M5

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202601
    Fiscal year ending Dec 31, 202701
    Quarter ending Mar 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 41.3% from $1.60.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$0.94$1.52$1.71$1.60$1.60-41.4%
    Fiscal year ending Dec 31, 2027$3.19$2.37$2.68$2.50$2.50+27.6%
    Quarter ending Mar 31, 2027$0.52$0.37$0.14$0.19$0.21+145.5%

    Frequently Asked Questions About PTCT

    What is the PTCT stock forecast?

    Consensus analyst estimates put PTC Therapeutics's EPS at $0.94 for the fiscal year ending Dec 31, 2026, on revenue of $1.32B. The consensus rating from 15 analysts is Buy.

    How do analysts rate PTCT stock?

    Of 15 analysts covering PTC Therapeutics, 4 rate it Strong Buy, 9 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from PTCT next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.94, with estimates from $0.73 to $1.14 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.19, with estimates from $3.04 to $3.34 from 2 analysts.

    What revenue do analysts expect from PTC Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.32B, with estimates from $1.29B to $1.34B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.43B, with estimates from $1.18B to $1.67B.

    How many analysts cover PTCT?

    15 analysts rate PTC Therapeutics stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.